louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05445232: A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
Official title: A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Obesity
Keywords: Overweight
Obesity
Drug Interaction
Cocktail
Pharmacokinetic
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2022-07-06
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Brief summary: The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.


Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) within the range 27.0 to 40.0 kilograms per meter squared (kg/m²)
* Male and female participants of childbearing potential who agree to use contraceptive methods

Exclusion Criteria:

* Have a history of diabetes or current diagnosis of diabetes
* History or presence of a of significant bleeding disorder
* Participants with significant comorbidity
* Participants receiving treatment with midazolam, warfarin, inhibitors or inducers of cytochrome P450 (CYP) -1A2, CYP2C9, or CYP3A4 enzymes, or drugs are CYP substrates and have a narrow therapeutic index

Primary outcomes:
measure: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam
timeFrame: Predose up to 24 hours postdose
measure: PK: Maximum Observed Concentration (Cmax) of Midazolam
timeFrame: Predose up to 24 hours postdose
measure: PK: AUC[0-∞] of Warfarin
timeFrame: Predose up to 96 hours postdose
measure: PK: Cmax of Warfarin
timeFrame: Predose up to 96 hours postdose
measure: PK: AUC[0-∞] of Caffeine
timeFrame: Predose up to 48 hours postdose
measure: PK: Cmax of Caffeine
timeFrame: Predose up to 48 hours postdose
Secondary outcomes:
Other outcomes:
Locations:
city: Daytona Beach
country: United States
facility: Covance Clinical Research Unit
state: Florida
city: Dallas
country: United States
facility: Covance Dallas
state: Texas
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT05213832: Effect of Inhalatory Sedation in Subarachnoid Hemorrhage
Official title: Effect of Inhalatory Sedation on Cerebral Perfusion in Subarachnoid Hemorrhage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage
Keywords: perfusion
isofluorane
inhalatory
sedation
Lead sponsor: A.O.U. Città della Salute e della Scienza
Sponsor class: OTHER
First posted: 2022-01-28
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to evaluate the effect of inhalational sedation on cerebral perfusion in patients with SAH.

It will evaluate whether the administration of isofluorane, by inducing direct vasodilation in the cerebral parenchyma, can improve the cerebral perfusion rates.

Perfusional CT will be used to study the variation of cerebral blood flow to rule out the vasodilatory effect on territories with different cerebrovascular reactivity aggravating the phenomena of distrectual hypoperfusion (theft theory).


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years old
* Diagnosis of non-traumatic SAH
* Neurological and/or systemic presentation that requires support of vital functions and sedation. This occurs for a WFNS score (World Federation of Neurosurgical Societies) ≥ 3.
* Possibility of ICP monitoring through EVD which is necessary in case of acute hydrocephalous. In case of the neurosurgeon do not indicate the positioning of the EVD, an intraparenchymal catheter will be positioned for the ICP monitoring.
* Patients with vasospasm (area of cerebral blood flow under 30% of the best value detected in the brain of the patients at the first CT scan). This exam will be performed at 2° - 3° day post event.
* Acceptance of informed consent.

Exclusion Criteria:

* Documented outcomes of cerebrovascular disease
* Patients with acute heart failure related to ESA
* State of pregnancy
* Patients with CLCR \< 30 mL/min

Primary outcomes:
measure: Cerebral blood flow recondtion
timeFrame: 20 minutes
Secondary outcomes:
measure: Changes in intracranial pressure during isoflurane delivery
timeFrame: 20 minutes
measure: Changes in blood pressure during isoflurane delivery
timeFrame: 20 minutes
Other outcomes:
Locations:
city: Torino
country: Italy
facility: AOU Città della Salute e della Scienza - Presidio CTO
Study officials:
affiliation: AOU Città della Salute e della Scienza
name: Maurizio Berardino, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05631132: May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
Official title: May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Interstitial Lung Disease
Keywords: Bronchoalveolar Lavage
Noninvasive Mechanical Ventilation
Continuous Positive Airway Pressure
Bronchoscopy
Lead sponsor: Medical University of Silesia
Sponsor class: OTHER
First posted: 2022-11-30
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The objective of our project is to find procedures and/or parameters to predict the diagnostic recovery (≥ 60% of the administered fluid volume) of bronchoalveolar lavage (BAL) fluid before bronchoscopy and to assess the impact of using non-invasive mechanical ventilation (NMV) or continuous positive airway pressure (CPAP) to achieve diagnostic recovery in patients with chronic obstructive pulmonary disease (COPD) and interstinal lungs disease for whom BAL performed during ordinary bronchoscopy turns out to be non-diagnostic.


Eligibility criteria: Inclusion Criteria:

1. Patients with diagnosed stable COPD (Stages 1-3) - experimental group; Patients with interstitial lung disease - experimental group
2. Former and current smokers with normal lung function - potential control group 1;
3. Never-smokers with normal lung ventilation - potential control group 2.

Exclusion Criteria:

1. No written, informed consent to participate in the research project.
2. Severe respiratory failure (SaO2 \< 90%)
3. The patient qualified for home oxygen treatment or home mechanical ventilation
4. Severe heart failure (NYHA class IV)
5. COPD mMRC IV
6. Myocardial infarction in the last two weeks or unstable angina
7. Severe, particularly ventricular arrhythmias
8. Platelet count \< 20,000/ul
9. INR \> 2 or APPT \> 36 sec
10. Very severe obstruction: forced expiratory volume in 1 second (FEV1) \< 30% of predicted.

Primary outcomes:
measure: May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Katowice
country: Poland
facility: Pulmunology Department
Study officials:
References:
Clinical trial NCT00657332: Clinical and Pathologic Studies in Neuroendocrine Tumors
Official title: Clinical and Pathologic Studies in Neuroendocrine Tumors
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Carcinoid Tumor
Neuroendocrine Tumors
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2008-04-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: neuroendocrine tumor patients

Brief summary: This research involves the study of neuroendocrine tumors in order to better understand how the disease grows and spreads. This study requires will use tissue collected from from biopsies performed during your regular medical care (i.e. tissue leftover after your diagnosis has been made) and/or blood and urine samples. This study may lead to the development of special materials that could be used, in the future, to treat neuroendocrine tumors or to follow the response of neuroendocrine tumors to treatment


Eligibility criteria: Inclusion Criteria:- Patients are eligible if they have a histologically proven neuroendocrine tumor and are 18 years of age or older

- Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Stanford University
name: George Albert Fisher M.D. Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05278832: A Study of QLS31905 in Patients With Advanced Solid Tumors
Official title: A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of QLS31905 in Patients With Claudin18.2-positive Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Advanced Solid Tumors
Lead sponsor: Qilu Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2022-03-14
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.


Eligibility criteria: Inclusion Criteria:

1. Written informed consent.
2. ≥18 years.
3. Female or male.
4. ECOG performance status score 0 or 1.
5. Histologically or cytologically confirmed diagnosis of advanced solid tumors.
6. Adequate haematological, hepatic and renal function.

Exclusion Criteria:

1. Any anticancer therapy or immunotherapy within 4 weeks prior to the start of study treatment.
2. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.
3. Patients with a history of monoclonal antibody allergic reaction.
4. Known human immunodeficiency virus infection or known symptomatic hepatitis.

Primary outcomes:
measure: Dose limiting toxicities(DLTs)
timeFrame: 2 years
measure: Maximum tolerated Dose(MTD)
timeFrame: 2 years
Secondary outcomes:
measure: Progression-free Survival (PFS)
timeFrame: 2 years
measure: Objective response rate (ORR)
timeFrame: 2 years
measure: Disease control rate (DCR)
timeFrame: 2 years
measure: adverse events (AE)
timeFrame: 2 years
measure: Cmax
timeFrame: 2 years
measure: AUC
timeFrame: 2 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT06571032: Electroencephalography in the Management of Neuroelectric Stimulation in Patients With Severe Traumatic Brain Injuries
Official title: Evaluation of Electroencephalography in the Management of Neuroelectric Stimulation in Patients With Severe Traumatic Brain Injuries: A Prospective Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Brain Injuries
Keywords: Electroencephalography
Severe traumatic brain injuries
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2024-08-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients have severe TBI and receive neuroelectral stimulation.

Brief summary: The goal of this observational retrospective study is to evaluate the electroencephalography (EEG)'s poficiency in the treatment of neuroelectric stimulation in patients with severe traumatic brain injuries (TBI).

The main questions it aims to answer are:

1. Whether EEG of patients with severe TBI will change after they receiving neuroelectrial stimulation? If yes, how does it change?
2. How can EEG be used to evaluate the condition of patients with severe TBI?


Eligibility criteria: Inclusion Criteria:

* 7 days after severe traumatic brain injuries (GCS score 3-8);
* Over 18 years old, regardless of gender;
* The patient's legal representative is informed and voluntarily signs the consent form.

Exclusion Criteria:

* Unstable vital signs;
* History of mental disorders or neurodegenerative diseases;
* Uncontrolled epilepsy;
* Severe arrhythmias or patients with implanted cardiac pacemakers;
* Various conditions that interfere with scalp EEG collection;
* Pregnant women.

Primary outcomes:
measure: CRS-R scores 6 months after the patient's discharge
timeFrame: 6 months
Secondary outcomes:
measure: CRS-R scores during hospitalization
timeFrame: 3 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Brain Injury Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
state: Shanghai
Study officials:
affiliation: RenJi Hospital
name: Junfeng Feng, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03232632: Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.
Official title: Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: EARLY_PHASE1
Conditions: Cardiac Amyloidosis
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2017-07-28
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.

Detailed description: Hypothesis had been performed that PET with 18F-Flutemetamol (Vizamyl®) could lead an early diagnostic. Indeed, this tracer had been recently used to highlight inter-cerebral beta-amyloid plaques on patients with Alzheimer Disease.

Because this labelling is performed on amyloid deposits, this tracer would lead to view and to quantify amyloid deposits within cardiac amyloid injuries.

Results of this PET will be combined with scan examinations for a better anatomic tracking.

Eligibility criteria: Inclusion Criteria:

* Patients followed for amyloidosis with proved cardiac injury or strongly suspected:

  * cardiac echography with typical signs of amyloid injury,
  * anatomical result confirming presence of amyloid deposits at cardiac or peripheral level
* Signature of Informed Consent Form,
* Affiliation to a social security system

Exclusion Criteria:

* Patient who suffers from another pathology which could lead cardiac injury (coronary disease, valvular disease, other pathology of deposit),
* Pregnancy and lactating women,
* Absence of effective contraception,
* Irradiating examination performed within the last 12 months or scheduled within the next 12 months,
* Unable patient physically, mentally or legally to provide informed consent,
* Patient under a system of legal protection

Primary outcomes:
measure: ratio Heart/ Upper Mediastinum
timeFrame: average of last 15 minutes
measure: standardized uptake value (SUV) measures
timeFrame: average of last 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Toulouse
country: France
facility: University Hospital Toulouse
Study officials:
affiliation: University Hospital, Toulouse
name: Eric OUHAYOUN, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06717932: A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
Official title: A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With CS-101 Transplantation
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Beta-Thalassemia
Lead sponsor: CorrectSequence Therapeutics Co., Ltd
Sponsor class: INDUSTRY
First posted: 2024-12-05
Enrollment: 8
Sex: ALL
Minimum age (years): 12
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subject with β-thalassemia treated with CS-101 infusion in CS-101-01 study

Brief summary: This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-01 (NCT06291961),No investigational drug product will be administered in the study.

Detailed description: This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-01 (NCT06291961). Subjects in the CS-101-01 study will be entered into long-term follow-up of this study up to 15 years post-infusion at the completion of the last (12-month) follow up visit after treatment with CS-101 Injection.

Eligibility criteria: Inclusion Criteria:

* Participants must have received CS-101 infusion in CS-101-01 study
* Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form

Exclusion Criteria:

* There are no exclusion criteria

Primary outcomes:
measure: Frequency and severity of SAEs and CS-101 related AES as assessed by CTCAE v5.0
timeFrame: Through 15 years post CS-101 infusion
measure: Occurrence of all-cause death
timeFrame: Through 15 years post CS-101 infusion
measure: Occurrence of achieving transfusion independence for at least 12 consecutive months
timeFrame: Through 15 years post CS-101 infusion
Secondary outcomes:
measure: Change in fetal hemoglobin(HbF) concentration over time
timeFrame: Through 15 years post CS-101 infusion
measure: Change in total hemoglobin(Hb) concentration over time
timeFrame: Through 15 years post CS-101 infusion
measure: Chimerism level in Peripheral blood Proportion of alleles with intended genetic modification in
timeFrame: Through 15 years post CS-101 infusion
measure: Chimerism level in bone marrow Proportion of alleles with intended genetic modification in
timeFrame: Through 15 years post CS-101 infusion
measure: Change in F-Cell concentration over time
timeFrame: Through 15 years post CS-101 infusion
Other outcomes:
Locations:
city: Nanning
country: China
facility: The First Affiliated Hospital of Guangxi Medical University
Study officials:
References:
Clinical trial NCT00559832: Prevention of Acute Mountain Sickness by Intermittent Hypoxia
Official title: Prevention of Acute Mountain Sickness by Sleeping at Simulated Altitude (Normobaric Hypoxia)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Mountain Sickness
Keywords: acute mountain sickness
intermittent hypoxia
acclimatization
Lead sponsor: Heidelberg University
Sponsor class: OTHER
First posted: 2007-11-16
Enrollment: 75
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Acclimatization by mountaineering prior to high altitude sojourns have shown to be effective in prevention of acute mountain sickness (AMS).

The aim of this study is to investigate whether intermittent exposure to normobaric hypoxia during sleep is also effective to prevent AMS.


Eligibility criteria: Inclusion Criteria:

* healthy

Exclusion Criteria:

* Altitude exposure above 2000 m 8 weeks prior or during the study

Primary outcomes:
measure: incidence of acute mountain sickness
timeFrame: during one night at 4500 m
Secondary outcomes:
measure: Sleep quality
timeFrame: during one night at altitude
measure: ventilatory acclimatization
timeFrame: during one night at altitude
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Sports Medicine, University Hospital
Study officials:
affiliation: University Hospital Heidelberg
name: Christoph Dehnert, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06372132: G-POEM vs PEG-J in Gastroparesis Patients
Official title: 'Treatment Outcome of Gastric Peroral Endoscopic Pyloromyotomy in Comparison With Percutaneous Endoscopic Gastrostomy With Jejunal Extension in Medically Refractory Gastroparesis: a Prospective Randomized Controlled Trial'
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Gastroparesis
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2024-04-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Study design: A randomized non-blinded controlled clinical trial with two study arms (G-POEM and PEG-J). Treatment success is measured using the GCSI at baseline before intervention and six months after intervention with a possible cross-over after six months of follow-up.

Study population: 50 patients with therapy refractory GP on dietary advices, prokinetics and possibly tube feeding (gastric rest) who have already been referred for additional treatment options in the form of PEG-J/ G-POEM.

Intervention: Group 1 will receive G-POEM treatment and group 2 will receive PEG-J treatment.

Main study parameters/endpoints: A clinically meaningful treatment success six months after G-POEM treatment, measured using the GCSI-score defined as a decrease of 1 or more point.


Eligibility criteria: Inclusion Criteria:

* Patients with GP
* 13C octanoic acid test or gastric scintigraphy (minimal 4-hour measurement) within the past twelve months
* 18 years old

Exclusion Criteria:

* \< 18 years old
* Medical history of stomach surgery in which resection of antrum and/ or pylorus took place
* Medical history of surgical or laparoscopic pyloromyotomy
* Gastric bypass
* Current opioid use
* Pregnancy

Primary outcomes:
measure: Number of patients with treatment success using the GCSI-score in patients with refractory GP undergoing G-POEM compared to patients receiving a PEG-J at t = 6 months.
timeFrame: 6 months
Secondary outcomes:
measure: Number of patients with treatment success using the GCSI-score in patients with refractory GP undergoing G-POEM compared to patients receiving a PEG-J at t = 12 months.
timeFrame: 12 months
measure: Degree of quality of life using the PAGI-QOL in the G-POEM group in comparison with the PEG-J intervention six months after intervention.
timeFrame: 6 months
measure: Number and severity of (s)AEs in the treatment groups.
timeFrame: 12 months
measure: Predictive value of the etiology of gastroparesis on treatment outcomes following G-POEM by measuring the rate of treatment success quantified by improvements in the GCSI-score.
timeFrame: 6-12 months
measure: Predictive value of the etiology of gastroparesis on treatment outcomes following PEG-J by measuring the rate of treatment success quantified by improvements in the GCSI-score.
timeFrame: 6-12 months
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Center
state: Zuid-Limburg
Study officials:
References: